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Sodium 2,3-dimercapto-1-propane sulfonate (DMPS, Dimaval) is a water-soluble chelating agent
that can be given by mouth or systemically and has been used to treat metal intoxication since the
1960s in the former Soviet Union and since 1978 in Germany. To better approximate the body
burdens of Hg and As in humans, DMPS-Hg and DMPS-As challenge tests have been developed.
The tests involve collecting an overnight urine, administering 300 mg DMPS at zero time,
collecting the urine from 0 to 6 hr, and determining the urinary Hg before and after DMPS is given.
The challenge test, when applied to normal college student volunteers with and without amalgam
restorations in their mouths, indicated that two-thirds of the Hg excreted in the urine after DMPS
administration originated in their dental amalgams. In addition, there was a positive linear
correlation between the amalgam score (a measure of amalgam surface) and urinary Hg after the
challenge test. When the DMPS-Hg challenge test was used to study dental personnel
occupationally exposed to Hg, the urinary excretion of Hg was 88, 49, and 35 times greater after
DMPS administration than before administration in 10 dental technicians, 5 dentists, and 13
nondental personnel, respectively. DMPS also was used to measure the body burden of humans
with a history of drinking water containing 600 pg As/liter. DMPS administration resulted in a
tripling of the monomethylarsonic acid percentage and a halving of the dimethylarsinic acid
percentage as related to total urinary As. Because South American animals studied were deficient
in arsenite methytransferase, a hypothesis is presented that arsenite and arsenite
methyltransferase may have had a role in the evolution of some South American animals.
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Concerns have increased about neurotoxi-
cants such as methylmercury in fish (1),
elemental Hg vapor emitted by dental
amalgams (2-5), lead in paint (6), and
inorganic arsenic (inorgAs) in the drinking
water of the United States (7), Chile
(8-10), Mexico (11), Argentina (12),
India (13,14), China (15), and Taiwan
(16). Because continued efforts to main-
tain clean living and working environ-
ments are necessary, the use of antidotes
and prophylactics (Table 1) for these toxic
heavy metals and metalloids are sometimes
minimized because of the fear that their
use might decrease efforts to maintain and
ensure a healthy environment.
Our laboratory had a role in the
development of two of the relatively new
chelating agents, DMPS [sodium 2,3-
dimercapto-1-propane sulfonate (Dimaval);
Heyl, Berlin, Germany] and DMSA (meso-
2,3-dimercaptosuccinic acid, succimer).
We developed analytical procedures for
their study (18,19), investigated their
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metabolism (20-25), and honed their
therapeutic uses (3,9,26,27). The purpose
ofthis paper is to review our studies ofthe
use ofDMPS as a challenge or provocative
test for Hg (3,26,27) andAs in humans (9).
A number of reviews dealing with DMPS
and DMSAare available (17,28-32).
Although BAL (British Anti-Lewisite,
dimercaprol, 2,3-dimercapto-1-propanol)
has been the drug ofchoice for the treat-
ment ofAs, lead, and even Hg intoxica-
tion in the United States since the late
1940s, it has many disadvantages (33).
Approximately 55% ofthe patients receiv-
ing BAL have some kind of unpleasant
side effect (33). This and the fear of the
As-containing chemical warfare agent
Lewisite resulted in the development of
two water-soluble, orally useful chemical
analogs ofthe lipid-soluble BAL.
DMPS was developed in the 1950s in
the former Soviet Union by Petrunkin
(34) and became an official drug in the
Soviet physician's armamentarium in 1958
(35). Because it had potential use as an
antidote for the chemical warfare agent
Lewisite, it was not available outside ofthe
Soviet Union until 1978, at which time
Heyl, a small pharmaceutical company in
Berlin, Germany, specializing in antidotes,
announced its synthesis and distribution.
Since then, it has been widely used as a
chelating agent for both diagnostic
and treatment purposes, especially in
Germany, where for many years a physi-
cian's prescription was not required for its
purchase (36). Its major use has been for
mobilizing inorganic Hg in the body
[reviewed by Kemper et al. (17), Aaseth
et al. (28), Aposhian et al. (29), and
Aposhian (30)] It has been used largely
because of the increasing concerns about
elemental Hg emission from dental amal-
gams in vivo (2-5) and about dental per-
sonnel exposed occupationally to Hg
(26,37). DMPS is approved for use in
Germany. It is still an investigational drug
in the United States where an investiga-
tional new drug permit (IND) is required
for its research use in humans. A compas-
sionate IND can be obtained quickly from
the U.S. Food and Drug Administration
for DMPS use in emergencies such as life-
threatening situations.
DMPS capsules (Dimaval) were gifts
ofHeyl (Berlin, Germany). It is appropri-
ate to note that in Europe DMPS is man-
ufactured and distributed by three
different companies. Only Heyl's Dimaval
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Table 1. Indications and contraindications of chelating agents in heavy metal poisonings (provisional recommen-
dations).
Metal First choice Second choice Contraindication
Hg metal DMPS DMSA Dimercaprol
Hg inorganic DMPS DMSA Dimercaprol
Hg organic DMSA DMPS Dimercaprol
Pb DMSA DMPS Dimercaprol, EDTA (?)
As DMPS, DMSA Dimercaprol Dimercaprol (?)
Cr DMPS
Sb DMPS -
Transuranics DTPA
Data from Kemper et al. (17).
is manufactured by approved Western
pharmaceutical procedures.
Since the development in the 1940s of
chelating agents for therapeutic use in
metal and metalloid poisonings, DMPS
and DMSA have been the most selective
and specific. Of these two orally useful
chelating agents, DMPS has at least three
advantages. First, it appears to remain in
the body for a longer time than DMSA
(25). Second, it acts more quickly than
DMSA, probably because its distribution is
both extracellular and intracellular (38,39).
DMSA, however, appears to be only extra-
cellular in its distribution (39). Third,
preparations of DMPS are available for
intravenous or intramuscular use. An intra-
venous preparation is a distinct advantage
when metal toxicity has been so severe that
the poisoned patient must be put on dialy-
sis or when immediate use in the emer-
gency room is necessary. DMSA, however,
is available only in capsule form. In
Amalgams
addition, the original licensing ofDMSA
by Johnson & Johnson Baby Products
(Skillman, NJ) and to McNeil (Fort
Washington, PA) and eventually to two
smaller pharmaceutical companies has
made its availability questionable, to say
the least. For example, DMSA appears to
be unavailable for human research or thera-
peutic use in Europe at this time. Themajor
research interest in DMSA at present
appears to be a large-scale dinical trial in the
United States to ascertain whether it can
reverse some ofthe cognitive damage pro-
duced bychronic lead exposure in U.S. chil-
dren. Unfortunately, the trial appears to be
moving slowly because oflow enrollment
and compliance.
A number of years ago we began to
evaluate the use of DMPS as a challenge
test for Hg. We used the oral capsules
(Dimaval) in most of our studies
(3,26,27). Other investigators have used
the injectable preparations (Dimaval) for
challenge tests (40,41). However, we used
the parenteral preparation for our intra-
venous pharmacokinetic studies (25). We
prefer using DMPS capsules because ofthe
ease of administration and because side
effects to most drugs are less likely to occur
when theyare given orally.
Increased Urinary
Excretion of Mercury
Normal Humans
There has been considerable controversy
whether the elemental Hg emitted from
dental amalgams in humans causes adverse
health effects and whether this Hg adds to
the body burden of this extremely toxic
heavy metal (2,42). Most dental amalgams
contain as much as 50% metallic Hg. To
determine whether dental amalgams influ-
ence the body burden ofHg, college stu-
dents (15 males and 5 females) with and
without dental amalgams were chosen as
subjects. The diameters ofeach ofthe sur-
faces ofall the dental amalgam restorations
in each subject's mouth were measured, a
score determined for each surface, and the
scores summed to obtain theamalgam score
(3). After an overnight fast, administration
ofthree 100-mg DMPS capsules by mouth
increased the mean urinary Hg excretion of
the amalgam group and the nonamalgam
group over a 9-hr period (Figure 1; Table
2). Our first conclusion from these experi-
ments (2) was that DMPS can be used to
increase the urinary excretion ofHg, a con-
firmation of many studies by others
(43,44). Our second conclusion was that
two-thirds ofthe Hg excreted in the urine
ofsubjects with dental amalgams appeared
to be derived from the Hg vapor released
from their amalgams (Figure 1). Linear
regression analysis indicated a highly signif-
icant positive correlation between the Hg
excreted in the urine 2 hr after DMPS
administration and the dental amalgam
scores (Figure 2). The third conclusion was
that because the urinary Hg concentration
ofnormal individuals is barelydetectableby
the cold vapor atomic absorption analytical
procedure we used, the significance and
reliability ofthese measurements can be
increased bydetermining urinary Hg after a
DMPS challenge.
DentalTedimicians, Dentists,
andNondental Personnel
We were asked to evaluate the Hg body
load ofdental personnel working in a new
facility in a developing country. For eco-
nomic reasons, the dental technicians in
this clinic formulate the dental amalgam as
needed by taking a few drops ofHg from a
bottle and putting them on a piece offilter
paper. They add to this some amalgam
alloy and carry it to the dentist, who
o 1 f -
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Figure 1. Urinary Hg before and after administration of
300 mg DMPS to volunteers with and without dental
amalgams.
Table 2. Urinary mercury excretion before and afterthe oral administration of 300 mg DMPS to normal individuals with and without dental mercury amalgams.
Group, pg Hg±SEa
No amalgam Amalgam p
-9to 0 hr 0.27±0.04 0.70±0.11 <0.002
Oto 9 hr 5.10±1.11 17.16±3.32 <0.003
p <0.001 <0.001 -
'n= 10 for each group. DMPS was given at zero time.
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Figure 2. Amalgam score versus urinary Hg excretion after DMPS administration. The Hg excretion after DMPS
administration has been corrected by subtracting the Hg excretion found for the same length of time prior to
administering DMPS. This was done by collecting the urine for 11 hr before DMPS administration and determining
the mercury content per 11 hr, then calculating the mercury excretion per hour. R, coefficientof correlation.
squeezes out the excess Hg. Because of our
findings (26) as to the amount of Hg
excreted by the dental technicians after
DMPS was given (Figure 3), the clinic has
begun to use amalgam capsules. In these
capsules, the Hg and alloy powder are sep-
arated by a partition, which is broken by
shaking the capsule vigorously. Thus, the
amalgam is formulated with less Hg expo-
sure to dental personnel.
The DMPS challenge test (300 mg by
mouth after an 1 1-hr fast; Table 3) was
given in Monterrey, Mexico, to 10 dental
technicians (all females), 5 dentists (4
males and 1 female), and 13 nondental
personnel (8 males and 5 females) to ascer-
tain their occupational exposure to Hg
used in the preparation ofamalgams (26).
Urines were collected and analyzed for
total Hg. Mean Hgurinarf-excretion 6 hr
before and 6 hr after DMPS administra-
tion for the dental technicians (who for-
mulate amalgam) was 4.84 pg ± 0.742
standard error (SE) and 424. pg ± 84.9 SE;
for the dentists (who use amalgam in their
practice) 3.28 pg ± 1.1 1 SE and 162.0
pg ± 51.2 SE; and for the nondental per-
sonnel 0.783 pg±0.189 SE and 27.3
pg ± 3.19 SE. (These control values appear
to be different from the nondental personnel
values in the "Normal Humans" section.
This may be due to economic and dietary
differences because this group consisted of
laborers and the previous group consisted of
research laboratory and medical personnel.)
The increase in urinary Hg excretion
before and after DMPS administration was
considerable (Figure 3). The urinary
coproporphyrin levels before DMPS
administration, indicative ofrenal Hg con-
tent, were quantitatively associated with
the urinary Hg levels among the three
study groups after DMPS administration
(26). This was not so when the urinary Hg
before DMPS administration was com-
pared to urinary coproporphyrin. Thus it
appears that the urinary Hg level after
DMPS administration is a better indicator
of exposure and renal Hg burden than the
Hg measured in the urine before DMPS is
given. Regression analysis showed that the
coefficient of urinary Hg was statistically
and adversely associated with complex
attention (switching task), the perceptual
motor task (symbol-digit substitution),
symptoms, and mood. The easily per-
formed DMPS-Hg challenge test is useful
for monitoring humans for Hg vapor expo-
sure (26).
FactoryWorkers, Skin Lotion Users,
and Controls
We previously administered the DMPS
challenge test to humans exposed to the
elemental Hg (vapor) ofamalgams (3,26),
but not to mercurous salts. The challenge
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Figure 3. Increase of urinary mercury excretion after
Dimaval challenge test of dental technicians, dentists,
and controls in Monterrey, Mexico.
Table3. DMPS challenge test for mercury.
Time Action
-11 toO hr Begin fast
Begin overnight urine collection
0 hr End overnight urine collection
No breakfast, no coffee, notea
Administerthree 100-mg DMPS
capsules
Begin 0 to 6 hrurine collection
+4 hr Eatchicken orturkeysandwich
+6 hr Empty bladder, end both urine
collection andthefast
Acidify urine and freeze until analyzed
Analyze fortotal Hg bycold vapor
atomic absorption
test was given to 11 factory workers who
made a skin lotion containing mercurous
chloride, 8 users of the skin lotion, and 9
controls (27). Urines were analyzed for
total Hg by using cold vapor atomic
absorption spectrophotometry. The Hg
excreted for 6 hr before and 6 hr after
DMPS administration was 113 pg ± 26 SE
and 5037 pg ± 682 SE for the skin lotion
makers; 16.2 pg±3.4 SE and 1410
pg ± 346 SE for the skin lotion users; and
0.49 pg±0.11 SE and 18.4 pg± 7.1 SE for
the controls, respectively (Table 4). The
increases in urinary Hg resulting from the
DMPS-Hg challenge test were 45-, 87-,
and 38-fold, respectively. The results
demonstrate that in humans exposed to
mercurous chloride, DMPS increased the
urinary excretion of Hg and that the
DMPS-Hg challenge test is ofvalue for a
more realistic estimation ofmobilizable Hg
in humans (27).
Environmental Health Perspectives * Vol 106, Supplement 4 * August 1998
35-
30 -
25-
20 -
15-
10-
CD
=L
0
._-
L- CD
-0
a,
C.)
X C,
0,)
1
1
lOt9H.V. APOSHIAN
Table 4. Urinary mercury before and after DMPS challenge test.
pg Hg±SEM
Group -6 to 0 hr(before) 0 to+6 hr(after)
Skin lotion makers 113 ± 26(11) 5037 ± 682(11)
Range 16.0 -314 1728 - 10,307
Skin lotion users 16.2 ± 3.4(8) 1410 ± 346(8)
Range 1.84 -35.3 71.8 -3075
Controls 0.49 ± 0.11 (8) 18.4 ± 7.1 (8)
Range 0.07 -0.98 3.17 -54.2
For urinary Hg before vs after DMPS treatment: p<0.001 for lotion makers; p<0.002 for lotion users; and p<0.05
forcontrols. For-6 to 0 hr: makers versus controls, p<0.002; users versus controls, p<0.001; makers versus users,
p<0.01. For +6 to 0 hr: makers versus controls, p<0.001; users versus controls, p<0.001; makers versus users,
p<0.001. Numbers in parentheses equal number ofsubjects included in the mean.
Figure 4. Map showing locations of San Pedro de Atacama and Toconoa in the Antofagasta Province of Chile.
Data from Hopenhayn-Rich (10).
DMPS-Arsenic
Challenge Test
In May 1995 we were given the opportu-
nity to study how the DMPS challenge test
might alter the urinary As in humans
chronically exposed to As in their drinking
water. San Pedro de Atacama in Chile was
our study town. It is a relatively isolated
town in the Atacama Desert in northeast
Chile (Figure 4). The drinking water for
San Pedro de Atacama is obtained from a
river having an As concentration of 593
pg/I. The water has contained high levels
ofAs for centuries. The source ofthe As is
the runofffrom high volcanic formations
in the Andes. Toconao, the control town,
is about a 1-hr drive beyond San Pedro de
Atacama. Residents of Toconao drink
water containing about 19 pg As/l. The
protocol for the DMPS-As challenge test
(Table 5) differs from the DMPS-Hg chal-
lenge test (Table 3) only by the urine
collection schedule.
Table5. DMPS-arsenicchallenge protocol.a
Time Action
-11 to 0 hr Begin fast
Begin overnight urine collection
0 hr End overnight urine collection
No breakfast, no coffee, notea
Administerthree 100-mg DMPS
capsules
Begin 0-2 hr urine collection
2 hr End0-2 hr urine collection
Begin 2-4 hr urine collection
4 hr End 2-4 hr urine collection
Begin 4-6 hr urine collection
Eatchicken orturkey sandwich
6 hr End 4-6 hrurine collection
Begin 6-24 hrurine collection
11 hr Eatdinner
24 hr End 6-24 hrurine collection
&Physical examination and vital signs were measured
before and after the study. All urines were acidified
and frozen until analyzed for As species by hydride
generation atomic absorption.
Arsenate
OH
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Figure 5. Putative pathway for biotransformation of
arsenate/arsenite. GSH, glutathione; SACH, S-adenosyl-
homocysteine; SAM, S-adenosylmethionine.
AmountofArsenicSpecies
inUrine
The amount ofAs species in urine is often
considered an indication of chronic As
exposure. The species are the result ofthe
biotransformation of inorgAs (Figure 5).
Although the concentrations ofthe various
As species in the urine after the DMPS
challenge were determined (9), the
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Figure 6. Total arsenic excreted in the urine before and
after administration of 300 mg DMPS by mouth. DMPS
was given at zero time. Although urine was collected
overnight (-11 to 0 hr) and for 6-24 hr, the total amount
of arsenic excreted for these times was divided by 5.5
and 9to make the data comparable tothe 2-hr urine col-
lection periods of0-2, 2-4, and4-6 hr. Error bars±SE.
amounts of these species were ofgreater
interest because they are a better indicator
ofthe body burden ofAs. As compared to
the period before DMPS administration,
the mean total As (TotAs) in the urine of
the San Pedro de Atacama subjects
increased approximately 4-fold during the
2-hour period after DMPS (Figure 6).
When the San Pedro de Atacama and
Toconao subjects were compared, there
was a striking difference noted between the
mean amount of TotAs excreted in the
urine during all time periods (Figure 6).
This was not surprising because residents
ofthe two villages drink water containing
vastly differentAs concentrations (9).
It was surprising that there was a
marked increase in the amount of urinary
monomethylarsonic acid (MMA) being
excreted in the urine ofboth the San Pedro
and Toconao groups after DMPS was
given (Figure 7). There was approximately
a 9-fold increase in urinary MMA during
the 2-hr period after DMPS administration
as compared to the previous 2 hr. For the
same time periods, urinary inorgAs was
increased about 5-fold and dimethylarsinic
acid (DMA) less than 2-fold. From 2 to 6
hr after DMPS, the amount of inorgAs,
MMA, and DMA did not change to any
great extent. For the Toconao subjects,
although the absolute amounts of As
species per 2-hr period were much less, the
fold increases relative to the preceding time
period were similar.
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PercentofArsenicSpecies
intheUrine
The percentage that a urinary A
of the total urinary As has beer
criterion ofthe normal biotrans
or metabolism ofAs in a given s
in a given individual (45). The
ing change in our Chilean stud
the percent MMA increased to
never seen in anypreviously repc
in humans or animals (Figur
mean increased from 15% (Sar
Atacama) and 12% (Tocona
DMPS administration to 429
group during the 0- to 2-hr p(
DMPS. The usual percentage
reported in human urine has had
10 to 20% (46-48). The incre
cent MMA appeared to be accon
a substantial decrease in perci
The changes in the percent of
species for the Toconao group
similar to those found for the Sa
Atacama group (Figure 8).
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Figure 8. Arsenic species expressed as a percentage
of urinarytotal arsenic attime periods before and after
B[ | DMPS administration. DMPS (300 mg) was given by
mouth at zero time. Percentages forthe Toconao group
are in parentheses. Arrow denotes DMPS given at
rsenic, MMA, 0 time.
ore and after
[A) San Pedro
trol)subjects. The percent inorgAs in the urine trinewasucol- increased after DMPS administration
14hr, thetotal (Figure 8). By the end of 6 hr it had
as divided by decreased to 28 and 24% for San Pedro de
:acomparable Atacama and Toconao, respectively. For
)-2, 2-4, and urinary DMA, however, the percentage
decreased after DMPS. Although DMPS
administration resulted in significant
changes in the percent ofthese various As
species excreted in the urine of both San
Pedro de Atacama and Toconao subjects,
.s species is the magnitude of the changes in relative
i used as a percent was essentially the same for both
sformation groups (Figure 8).
species and
most strik- Other Observatons
ly was that There were no signs ofAs toxicity in the
an extent San Pedro de Atacama residents as far as
Drted study skin keratosis and ulcerations. The lack of
re 8). The toxic signs and symptoms of chronic As
n Pedro de toxicity is highly unusual. One cannot help
lo) before but wonderwhether the difference between
Jo for each the San Pedro subjects, where exposure has
eriod after continued for at least 10,000 years, and the
of MMA victims ofAs exposure in Taiwan, Mexico,
1 a range of and India, where exposure is relatively
ase in per- recent, is a matter ofpolymorphism or sur-
npanied by vival ofthe fittest. Along these lines, recent
ent DMA. studies from our laboratory (49-51) indi-
urinary As cate South American animals lack the
were very enzymes responsible for the methylation of
in Pedro de inorganic arsenite to the supposedly less
toxic methylated As species.
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Doesthe Lack of Methylation
ofArsenite and MMA Have
an Evolutionary Significance?
When arsenite is given to humans, rhesus
monkeys, rabbits, rats, hamsters, mice, or
dogs, they excrete MMA and DMA in their
urine (45). The relative amounts ofthese
two urinary metabolites ofarsenate/arsenite
in the urine differ depending on the animal
species (45). The marmoset (52,53) and
chimpanzee (54), however, do not excrete
MMA or DMA. While seeking the best
species and tissue source from which to
purify (55) the methyltransferases of arsen-
ite metabolism, we discovered a striking
diversity in the amounts ofthese enzymes
in various species. Our in vitro enzyme
experiments (Figure 9) show that the expla-
nation for this unusual excretion profile is
that the marmoset monkeyand chimpanzee
are deficient in or lack active arsenite
methyltransferase(s) (49,56). The mar-
moset is a New World monkey. An Old
World monkey, the rhesus, has ample As
methyltransferase activity. The chimpanzee
is a subhuman primate from the Gold
Coast of western Africa and Nigeria.
Geographically, western and central Africa
are between the rain forests of South
America and the plains ofIndia. The rhesus
monkey seems to have evolved mainly from
the India subcontinent. Our future plans
are to try to narrow these geographic areas
ofarsenite methyltransferase diversity.
What is the purpose ofthese deficiencies
in arsenite and MMA methyltransferase?
Does it give animals a selective advantage of
some kind? There is a reasonable hypothesis
that can be offered to help explain such a
deficiency in certain animals. There is no
question that the hypothesis is a speculative
one but it can serve as a basis for future
investigation and understanding. We pro-
pose that a deficiency ofthese methyltrans-
ferases and/or perhaps polymorphism may
have allowed high levels ofarsenite to be
maintained in the blood and liver ofsome
South American species in their ancient
(e.g., South American) habitat. The lack of
arsenite methyltransferases may have been
ofsome evolutionary benefit for those ani-
mals deficient in it. What might be the
benefit? The lack ofmethylation of inor-
ganic arsenite by these species could be a
selection process for survival under certain
environmental conditions. For example,
South American animals are exposed to
Trypanosoma cruzi and the chimpanzee in
Africa to Trypanosoma brucei. A major evo-
lutionary demand is the preservation ofthe
species. The lack ofthe arsenite methylat-
ing enzymes in the marmoset (49), tamarin
(49), and squirrel monkeys (56), guinea
pig (50), and chimpanzee (56) may be the
result ofevolutionary selection necessary for
survival ofthe species in an environment
containing lethal trypanosomes or other
pathogens in South America and Africa.
We propose that ifthese animals had been
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able to methylate inorganic arsenite, they
would not have survived. By not methylat-
ing arsenite, the blood and liver levels of
inorganic arsenite would be expected to be
high and possibly act as a prophylactic or
treatment for trypanosomiasis. Trivalent
arsenicals have antiinfectiveproperties.
What support does such a hypothesis
have? First ofall, to the present all the ani-
mal species (except one) that are deficient
in the As methyltransferases are believed to
have evolved in the NewWorld, specifically
in South America. Second, river water in
South America is often high in arsenate/
arsenite. The high As content of South
American water is believed to be due to the
runoff from volcanic ash in the Andes
Mountains. Third, the trivalent arsenical
melarsen oxide has been the drug ofchoice,
until recently, to treat late-stage African try-
panosomiasis Trypanosoma bruceigambiense
(sleeping sickness). Its mechanism ofaction
is thought to be the formation ofan adduct
with reduced trypanothione, a reduced glu-
tathionelike compound. Trypanothione is
N'N8-bis(glutathionyl)spermidine (Figure
10). It is the major intracellular thiol of T
brucei and other trypanosomes (57). In
fact, it makes up more than 68% of the
intracellular thiol ofthese organisms (58).
Melarsen oxide forms an adduct with
reduced trypanothione (Figure 10). The
adduct inhibits trypanothione disulfide
0
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Figure 9. Arsenite methyltransferases of liver cytosols ofvarious animals.
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Figure 10.Trypanothione and its melarsen oxide adduct.
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reductase, an enzyme unique and essential
to trypanosomatids and leishmania, result-
ing in a decrease of intracellular reduced
trypanothione. Fourth, Chagas' disease,
caused by Trypanosoma cruzi, is endemic in
South America. Fifth, up to now, the
exception to our hypothesis about only
NewWorld animals being deficient or lack-
ing arsenite and MMAmethyltransferases is
the chimpanzee, which appears to have
evolved in the Old World. The chim-
panzee's natural home, however, is the
northwestern and central area ofAfrica-an
area that once was bound to or had island
bridges to South America. In this area of
Africa, T bruceigambiense is endemic. It is
not unreasonable, then, to consider that at
one time the environment ofthe marmoset,
guinea pig, and chimpanzee may have had
something in common. Seventh, the
pigeon, rat, hamster, rhesus monkey, and
mouse have arsenite methyltransferase
activity and are considered Old World as
far as their evolution is concerned.
Buchet's group (59,60) and Thomas'
group (61,62) also studied the methyl-
transferases ofAs metabolism in rat liver
homogenates. We have now purified the
rabbit arsenite methyltransferase 4200-fold
and it is being analyzed for its amino acid
sequences. Once the sequences are known,
nucleotide probes can be synthesized that
may be useful in determining the occur-
rence ofthese enzyme activities in lympho-
cytes and other human material readily
available for biomarker studies, especially
in humans exposed to inorganic As in the
water they drink, the food they eat, and/or
the airtheybreathe.
Discussion
TheDMPS-MercuryChallengeTest
One might wonder why we think there is a
need for such a challenge test. Let us for a
moment consider the recent history oflead.
In 1970, the Centers for Disease Control
(CDC) considered a lead level of40 pg/dl
blood to be of medical concern (6). In
sharp steps (Figure 11), this has been
reduced to 10 pg/dl over a 17-year period.
There are many toxicologists, however, who
believe that there is no safe level oflead. A
50-
- 40-
> 30-
CD 20-
io m 10T
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Year
Figure 11. Blood lead levels considered elevated by
the CDCand the Public Health Service.
DMPS-Hg challenge test may help obtain
specific information so that the calamity
caused by lead among manyyoung children
in the United States will not be repeated
with Hg. At possible risk from Hg are
young children, women who obtain dental
care while pregnant, and their potentially
exposed fetuses. Whether the amount ofHg
emitted from dental amalgams can cause
harmful human health effects is at present
uncertain; the safety ofdental amalgams has
not been proven. One has only to look at
Figure 11, showing how the blood lead con-
centrations ofconcern have changed over
the last 20 years, to realize thatsuch changes
might also happen to urinary Hg levels of
concern. Investigators studying toxicology
and human health must determine whether
dental amalgam Hg is harmful or not.
Since our DMPS studies ofusers and
makers ofa mercurous chloride-containing
skin-lightening lotion (Table 3) were com-
pleted, a miniepidemic involving Hispanic
women in the southwestern states ofTexas,
New Mexico, Arizona, and California has
been declared by the CDC (63). Even
more surprising have been the elevated uri-
nary Hg levels ofsome oftheir young chil-
dren. According to the mothers' statements,
the lotion was not applied to the children.
Although resources were mobilized to
remove this lotion from Hispanic stores in
the United States, unfortunately no federal
funds were made available for physicians to
follow the health ofthese exposed women
ofchildbearing age and who belong to an
importantminoritygroup in ourcountry.
Our studies with DMPS show clearly
that urinary Hg after a DMPS challenge
test is a better indication ofthe body bur-
den ofHg in a human. Ifthe body is com-
pared to a coffee cup, the usual urinary Hg
concentration may be compared to the
overflow ofthat cup. Using DMPS would
be comparable to tipping the cup so that
the fluid pouring out would be more
indicative ofwhat previously remained in
the cup (body). Clinicians and research
investigators often consider urine differ-
ently. Many physicians consider heavy
metal concentrations in the urine an excel-
lent diagnostic tool. Researchers, however,
want to know about what was left behind
in the body, thus doing the damage. This is
why the DMPS challenge information is of
value. It uses the urine after a DMPS chal-
lenge to tell us more about what previously
remained in the body.
DMPS andArsenic
The results with DMPS and As are ofgreat
interest because the unique increase in uri-
nary excretion of MMA after DMPS
administration is very important. The
chemical structure of the DMPS-As
chelate being excreted is not known. The
form ofAs necessary for chelation must be
As"',. Could it be that the chelate is the elu-
sive MMA species containing AsIII, or is it
arsenite? We do not know the answer to
this question as yet but we are investigat-
ing. Other thoughts about the possible
mechanisms and significance of this
increase in the urinary MMA percent can
be found inAposhian et al. (9).
Finally, we wish to emphasize that these
arsenite methyltransferase enzymes have
species diversity as well as species polymor-
phism, and thus have potential as important
biomarkers for As exposure. In addition, the
lack ofthe arsenite-methylating enzymes in
marmoset, tamarin, and squirrel monkeys,
guinea pig, and chimpanzee may be related
to evolutionary selection necessary for sur-
vival in a hostile environment containing
death-causing parasites ofsome kind. The
animals that could methylate inorganic As
species did not survive. Those that could not
methylate did survive. This is our working
hypothesis that is nowunderinvestigation.
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